Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
Liu SY, Bao H, Wang Q, Mao WM, Chen Y, Tong X, Xu ST, Wu L, Wei YC, Liu YY, Chen C, Cheng Y, Yin R, Yang F, Ren SX, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Dong S, Zhang XC, Su J, Yang JJ, Yang XN, Zhou Q, Wu X, Shao Y, Zhong WZ, Wu YL.
Liu SY, et al. Among authors: xu st, xu sd, xu s.
Nat Commun. 2021 Nov 8;12(1):6450. doi: 10.1038/s41467-021-26806-7.
Nat Commun. 2021.
PMID: 34750392
Free PMC article.
Clinical Trial.